INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer's Disease Prior to Start of AAIC 2020
Stock Information for INmune Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.